NAMS
HealthcareNewAmsterdam Pharma Company N.V. · Biotechnology · $4B
What is NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company headquartered in Naarden, the Netherlands, focused on developing treatments for metabolic diseases. Its pipeline centers on a novel cholesterol-lowering drug candidate targeting an underexplored biological pathway.
The company is developing obicetrapib, a selective inhibitor of the Cholesteryl Ester Transfer Protein (CETP). This mechanism is designed to reduce LDL cholesterol — often called 'bad' cholesterol — while simultaneously raising HDL cholesterol, the 'good' kind. NewAmsterdam is not yet generating product revenue; it funds operations through capital raises as it advances obicetrapib through clinical trials toward potential regulatory approval.
NewAmsterdam Pharma was founded in 2021 and operates out of Naarden, the Netherlands.
- Obicetrapib — lead CETP inhibitor candidate for LDL-C reduction
- Metabolic disease pipeline targeting cardiovascular risk
- Clinical-stage research in lipid management
Is NAMS a Good Stock to Buy?
UQS Score rates NAMS as Poor overall, reflecting the early-stage nature of the business.
The Growth and Risk pillars both register as Neutral, suggesting the company's development trajectory and near-term risk profile are neither standout concerns nor clear advantages relative to clinical-stage peers. The pipeline's novel mechanism of action gives it a differentiated scientific angle in the cardiovascular metabolic space.
Both the Quality and Moat pillars are rated Weak — consistent with a pre-revenue company that has no established commercial franchise or durable competitive position yet. Valuation is rated Elevated, meaning the market is pricing in significant future success.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does NAMS pay dividends?
No — NewAmsterdam Pharma Company N.V. does not currently pay a dividend.
NAMS does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. All available capital is directed toward funding research, clinical trials, and regulatory activities. Income-focused investors should note that a dividend is unlikely until the company reaches commercial-stage profitability.
When does NAMS report earnings?
NewAmsterdam Pharma reports financial results on a quarterly cadence, consistent with US-listed equities.
As a pre-revenue clinical-stage company, quarterly reports focus primarily on cash runway, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Pipeline milestones and trial readouts tend to drive more market attention than earnings beats.
For the most recent quarter's results and pipeline updates, visit NewAmsterdam Pharma's investor relations page.
NAMS Price History
+234.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in NewAmsterdam Pharma Company N.V.?
Based on NewAmsterdam Pharma Company N.V.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
NAMS Long-term Outlook
The fundamental outlook for NAMS hinges almost entirely on clinical outcomes for obicetrapib. With Growth rated Neutral and Risk also Neutral, the UQS profile reflects a company at an inflection point — neither accelerating nor deteriorating, but carrying the binary uncertainty inherent to late-stage drug development. An Elevated Valuation rating suggests the current share price already embeds optimistic assumptions about regulatory and commercial success.
Growth drivers
- Potential regulatory approval of obicetrapib in LDL-lowering therapy
- Large addressable patient population with cardiovascular metabolic risk
- Differentiated CETP inhibitor mechanism with limited direct competition
Key risks
- Clinical trial failure or unexpected safety signals could be company-defining
- Elevated valuation leaves little margin of safety if timelines slip
- Pre-revenue status means continued dependence on external capital
NAMS vs Peers
NAMS operates in a competitive clinical-stage landscape alongside other mid-cap biotech companies pursuing differentiated therapeutic mechanisms.
Legend Biotech focuses on cell therapy for blood cancers, representing a different therapeutic modality and disease area than NAMS's metabolic focus.
Viking Therapeutics is developing treatments for metabolic and endocrine disorders, making it a closer thematic peer to NAMS in the weight and lipid management space.
ACADIA targets central nervous system disorders, giving it a distinct pipeline profile and commercial-stage revenue that separates it from NAMS's pre-revenue standing.
Frequently Asked Questions
What does NewAmsterdam Pharma do?
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing obicetrapib, a CETP inhibitor designed to lower LDL cholesterol and raise HDL cholesterol. The company focuses on metabolic diseases and cardiovascular risk reduction. It has not yet commercialized any product.
Does NAMS pay dividends?
No, NAMS does not pay a dividend. As a pre-revenue clinical-stage company, it reinvests all available capital into research and clinical development. Dividend payments are not typical for companies at this stage of development.
When does NAMS report earnings?
NewAmsterdam Pharma reports on a quarterly cadence. Because it is pre-revenue, reports center on operating expenses and cash position rather than traditional earnings metrics. Check the company's investor relations page for the latest schedule and results.
Is NAMS a good stock to buy?
UQS Score rates NAMS as Poor overall, driven by Weak Quality and Moat pillars alongside an Elevated Valuation. This profile reflects the high uncertainty of clinical-stage investing. Whether that risk-reward suits your portfolio depends on your individual investment criteria — the full UQS breakdown is available to Pro members.
Is NAMS overvalued?
The UQS Valuation pillar for NAMS is rated Elevated, suggesting the current market price reflects optimistic assumptions about obicetrapib's clinical and commercial success. Pre-revenue biotech valuations are inherently speculative and sensitive to trial outcomes.
How does NAMS compare to its competitors?
Compared to peers like Viking Therapeutics, Legend Biotech, and ACADIA Pharmaceuticals, NAMS is distinguished by its CETP inhibitor mechanism targeting lipid metabolism. Some peers have more advanced pipelines or commercial revenue, which affects their quality and moat profiles relative to NAMS.
What is NAMS's market cap bracket?
NAMS is classified as a mid-cap stock. For a clinical-stage biopharmaceutical company with no product revenue, this reflects market expectations around obicetrapib's potential rather than current business fundamentals.
Who founded NewAmsterdam Pharma?
NewAmsterdam Pharma was founded in 2021. Detailed founding information, including the founding team, is publicly available through the company's official website and investor relations materials.
Is NAMS a long-term quality investment?
From a long-term quality perspective, NAMS currently scores Poor on the UQS composite, with Weak Quality and Moat ratings. Long-term quality indicators would need to improve substantially — likely requiring successful commercialization of obicetrapib — before the profile strengthens. Pro members can track pillar changes over time.
What is the main competitive advantage of NewAmsterdam Pharma?
NewAmsterdam's potential advantage lies in obicetrapib's differentiated CETP inhibitor mechanism, which targets both LDL reduction and HDL elevation simultaneously. However, the UQS Moat pillar is currently rated Weak, reflecting that no durable commercial advantage has been established yet.
What sector does NAMS belong to?
NAMS operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Its focus on metabolic and cardiovascular disease places it in a high-need therapeutic area with significant long-term market potential if its pipeline succeeds.
Is NAMS a growth stock or value stock?
NAMS carries a Neutral Growth pillar rating and an Elevated Valuation rating, making it neither a classic growth stock with proven expansion nor a value opportunity. It is best characterized as a speculative clinical-stage name where the outcome depends on binary trial results.
Unlock Full NAMS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare NAMS against sector peers side by side
- ✓Track Quality, Moat, and Valuation changes over time
- ✓Get the full analyst-style risk and growth assessment
Pro Analysis
NAMS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 23.0 | 1.3 | 12.0 | 56.0 | 56.8 | 0.0 | +3.3 |
| May 8, 2026 | 19.7 | 0.0 | 12.0 | 56.0 | 36.9 | 0.0 | -3.3 |
| Apr 2, 2026 | 23.0 | 1.3 | 12.0 | 56.0 | 56.3 | 0.0 | — |
NAMS — Pillar Breakdown
Quality
— 1.3/100 (25%)NewAmsterdam Pharma Company N.V. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 56.0/100 (20%)NewAmsterdam Pharma Company N.V. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 56.8/100 (15%)NewAmsterdam Pharma Company N.V. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)NewAmsterdam Pharma Company N.V. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 12/100 (25%)NewAmsterdam Pharma Company N.V. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for NAMS.
Score Composition
Financial Data
More Stock Analysis
How is the NAMS UQS Score Calculated?
The UQS (Unified Quality Score) for NewAmsterdam Pharma Company N.V. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses NewAmsterdam Pharma Company N.V.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether NewAmsterdam Pharma Company N.V. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.